Quantitative Proteomic Study Reveals Amygdalin Alleviates Liver Fibrosis Through Inhibiting mTOR/PDCD4/JNK Pathway in Hepatic Stellate Cells
Our data demonstrated a potential pharmaceutical mechanism by which amygdalin alleviates liver fibrosis by inhibiting the mTOR/PDCD4/JNK pathway in HSCs, suggesting that PDCD4 is a potential target for the treatment of liver fibrosis.
Authors
- Shanhua Fang
- Qian Meng (ORCID: https://orcid.org/0000-0001-6894-6167)
- Hu Zhou (ORCID: https://orcid.org/0000-0001-7006-4737)
- Qian Liu (ORCID: https://orcid.org/0000-0001-8525-7961)
- Wei Liu (ORCID: https://orcid.org/0000-0002-5925-3059)
- Ping Liu (ORCID: https://orcid.org/0000-0002-6152-4508)
- Hui Huang (ORCID: https://orcid.org/0000-0002-6102-2815)
- Jiamei Chen (ORCID: https://orcid.org/0000-0001-9808-9610)
- Su-Jie Ru
Institutions
- Nanjing University of Chinese Medicine (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Shanghai Institute of Materia Medica (CN)
- Shuguang Hospital (CN)
- University of Chinese Academy of Sciences (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/dddt.s500439
- Citations
- 3
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Skolkovo Institute of Science and Technology
- Shanghai University of Traditional Chinese Medicine
- National Key Research and Development Program of China